Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 18/20 | 1.00 |
| ▸ | HSP90AB1 | P08238 | 18/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 7/20 | 0.79 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10149974 | 0.93 | HSP90AA1 (0.87) | HSP90AA1HSP90AB1ERBB2HSP90B1 | |
| SCHEMBL23819778 | 0.90 | HSP90AA1 (0.81) | HSP90AA1HSP90AB1ERBB2HSP90B1 | |
| SCHEMBL1864541 | 0.88 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1ERBB2HSP90B1 | |
| SCHEMBL23450478 | 0.88 | HSP90AA1 (0.79) | HSP90AA1HSP90AB1ERBB2 | |
| SCHEMBL27584530 | 0.87 | HSP90AA1 (0.77) | HSP90AA1HSP90AB1ERBB2HSP90B1 | |
| SCHEMBL4854328 | 0.87 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1ERBB2 | |
| SCHEMBL4462613 | 0.86 | HSP90AA1 (0.77) | HSP90AA1HSP90AB1ERBB2HSP90B1 | |
| SCHEMBL30583139 | 0.86 | HSP90AA1 (0.77) | HSP90AA1HSP90AB1ERBB2HSP90B1 | |
| SCHEMBL1859519 | 0.84 | HSP90AA1 (0.80) | HSP90AA1HSP90AB1ERBB2HSP90B1 | |
| SCHEMBL1864700 | 0.84 | HSP90AA1 (0.80) | HSP90AA1HSP90AB1ERBB2HSP90B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4661876-A1 | METABOLIC INHIBITORS AND METHODS OF MAKING AND USING THEREOF | University of Miami (US) | 2025-12-17 | — | — | EP | claimed |
| WO-2024168133-A1 | METABOLIC INHIBITORS AND METHODS OF MAKING AND USING THEREOF | UNIVERSITY OF MIAMI (US) | 2024-08-15 | — | — | WO | claimed |
| US-12616759-B2 | Uses of labeled HSP90 inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2026-05-05 | — | — | US | disclosed |
| EP-4682148-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2026-01-21 | — | — | EP | disclosed |
| EP-4661876-A1 | METABOLIC INHIBITORS AND METHODS OF MAKING AND USING THEREOF | University of Miami (US) | 2025-12-17 | — | — | EP | disclosed |
| US-12473288-B2 | Treatment of neurodegenerative diseases through inhibiton of Hsp90 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2025-11-18 | — | — | US | disclosed |
| US-20250340550-A1 | SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT | ABBVIE INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250161318-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | ABBVIE INC (US) | 2025-05-22 | — | — | US | disclosed |
| US-20250145587-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2025-05-08 | — | — | US | disclosed |
| US-20250090504-A1 | SMALL MOLECULE PEPTIDOMIMETIC FOR THE TREATMENT OF TAUOPATHIES | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-03-20 | — | — | US | disclosed |
| CN-112703004-B | Methods and compositions for cancer treatment using recombinant dendritic cells | 雷诺瓦罗生物制药公司 | 2025-02-14 | — | — | CN | disclosed |
| WO-2007143630-A2 | TREATMENT OF NEUROFIBROMATOSIS WITH HSP90 INHIBITORS | NEXGENIX PHARMACEUTICALS (US) | 2007-12-13 | — | — | WO | disclosed |
| US-7241890-B2 | Purine analogs having HSP90-inhibiting activity | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-07-10 | — | — | US | disclosed |
| WO-2007075572-A2 | ORALLY ACTIVE PURINE-BASED INHIBITORS OF HEAT SHOCK PROTEIN 90 | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070129334-A1 | Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-06-07 | — | — | US | disclosed |
| US-20070129334-A1 | Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-06-07 | — | — | US | disclosed |
| EP-1335920-A4 | SMALL MOLECULE COMPOSITIONS FOR BINDING TO HSP90 | SLOAN KETTERING INSTITUTEFOR C (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20040102458-A1 | Small molecule compositions for binding to hsp90 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2004-05-27 | — | — | US | disclosed |
| EP-1335920-A2 | SMALL MOLECULE COMPOSITIONS FOR BINDING TO HSP90 | Sloan-Kettering Institute For Cancer Research (US) | 2003-08-20 | — | — | EP | disclosed |
| WO-2002036075-A2 | SMALL MOLECULE COMPOSITIONS FOR BINDING TO HSP90 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340550-A1 | SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT | BCL2, BAD, BAX | HSP90AA1 192/4885HSP90AB1 117/4885ERBB2 1234/4885 |
| US-20250090504-A1 | SMALL MOLECULE PEPTIDOMIMETIC FOR THE TREATMENT OF TAUOPATHIES | MAPT, PSEN1, PSEN2 | HSP90AA1 532/4885HSP90AB1 332/4885ERBB2 4309/4885 |
| US-20070129334-A1 | Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 | HSP90AB1, HSP90AA1, HSP90AB2P | HSP90AA1 2/4885HSP90AB1 1/4885ERBB2 1609/4885 |
| US-20250161318-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | BCL2, BAX, BCL2L1 | HSP90AA1 765/4885HSP90AB1 453/4885ERBB2 2872/4885 |
| US-20040102458-A1 | Small molecule compositions for binding to hsp90 | HSP90AB1, ERBB2, HSP90AB2P | HSP90AA1 5/4885HSP90AB1 1/4885ERBB2 2/4885 |
| US-12616759-B2 | Uses of labeled HSP90 inhibitors | HSP90AB1, HSP90B1, HSP90AB2P | HSP90AA1 4/4885HSP90AB1 1/4885ERBB2 756/4885 |
| US-20250145587-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | HSP90AA1 3128/4885HSP90AB1 2807/4885ERBB2 2062/4885 |
| US-12473288-B2 | Treatment of neurodegenerative diseases through inhibiton of Hsp90 | HSP90B1, HSP90AB1, HSP90AB2P | HSP90AA1 4/4885HSP90AB1 2/4885ERBB2 3171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.